Financial Results Approval

The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Q1 FY27), as per Regulation 33 of SEBI Listing Regulations.

Standalone Financial Results (Q1 FY27)

  • Revenue from operations: ₹694.68 crore
  • Other income: ₹35.84 crore
  • Total Revenue: ₹730.52 crore
  • Profit before exceptional items and tax: ₹254.84 crore
  • Exceptional items: None (₹0 crore)
  • Profit before tax: ₹254.84 crore
  • Tax expense: ₹64.20 crore
  • Profit after tax: ₹190.64 crore
  • Other comprehensive income: ₹0.27 crore
  • Total comprehensive income: ₹190.91 crore
  • Paid-up equity share capital: ₹10.26 crore (Face value ₹2 per share)
  • Basic EPS: ₹37.18 (not annualized)
  • Diluted EPS: ₹37.13 (not annualized)

Consolidated Financial Results (Q1 FY27)

  • Revenue from operations: ₹1,045.08 crore
  • Other income: ₹35.09 crore
  • Total Revenue: ₹1,080.17 crore
  • Profit before exceptional items and tax: ₹318.36 crore
  • Exceptional items: None (₹0 crore)
  • Profit before tax: ₹318.36 crore
  • Tax expense: ₹75.05 crore
  • Profit after tax: ₹243.31 crore
  • Share of Loss from Joint Venture: Negligible (below rounding norms)
  • Total profit for the period: ₹243.31 crore
  • Other comprehensive income: ₹0.23 crore
  • Total comprehensive income: ₹243.54 crore
  • Basic EPS: ₹47.45 (not annualized)
  • Diluted EPS: ₹47.39 (not annualized)

Comparative Performance

Standalone Q1 FY27 vs Q1 FY26:

  • Revenue increased 34.5% from ₹542.95 crore to ₹694.68 crore
  • Profit after tax increased 69.5% from ₹112.76 crore to ₹190.64 crore
  • EPS increased from ₹22.74 to ₹37.18

Consolidated Q1 FY27 vs Q1 FY26:

  • Revenue increased 46.1% from ₹725.40 crore to ₹1,045.08 crore
  • Profit after tax increased 107.7% from ₹117.17 crore to ₹243.31 crore
  • EPS increased from ₹23.63 to ₹47.45

Exceptional Items Explanation

Pursuant to notification issued by the Ministry of Labour and Employment, existing labour laws were consolidated into four Labour Codes ("New Labour Codes") with effect from November 21, 2025.

Standalone impact:

  • Initially estimated incremental liability of ₹18.84 crore recognized for quarter and nine months ended December 31, 2025
  • Liability revised to ₹6.93 crore for year ended March 31, 2026
  • Excess provision of ₹11.91 crore reversed in financial results for quarter ended March 31, 2026

Consolidated impact:

  • Initially estimated incremental liability of ₹20.47 crore recognized for quarter and nine months ended December 31, 2025
  • Liability revised to ₹6.75 crore for year ended March 31, 2026
  • Excess provision of ₹13.72 crore reversed in financial results for quarter ended March 31, 2026

The Company continues to monitor notifications, rules and clarifications issued by State and/or Central Government authorities in relation to the New Labour Codes.

Capital Expenditure Approval

The Board approved capital expenditure of ₹90 crores for establishing adoption capacities to progress products forming part of Advanced Materials portfolio, from lab scale to commercial scale qualification at the Surat unit of the Company.

Capex Details:

  • Investment required: ₹90 Crores
  • Mode of financing: Internal accruals
  • Expected completion: Q2 of FY28 (September 2027 quarter)
  • Rationale: Incubate new value accretive business vertical as future growth driver and augment capabilities for commercial scale qualification supplies
  • Capacity metrics: Not applicable (new adoption capacities)

Audit Review

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. They have been subjected to limited review by the statutory auditors, Price Waterhouse Chartered Accountants LLP, who issued an unmodified review conclusion.

Subsidiaries and Joint Ventures Included

The consolidated results include:

  • Foreign subsidiaries: Manchester Organics Limited, NFIL (UK) Limited, Navin Fluorine (Shanghai) Co. Limited
  • Step-down foreign subsidiary: NFIL USA Inc. (100% subsidiary of NFIL (UK) Limited)
  • Indian subsidiaries: Sulakshana Securities Limited, Navin Fluorine Advanced Sciences Limited
  • Joint venture: Swarnim Gujarat Fluorspar Private Limited

Business Segment Information

The Company operates only in one Business Segment - 'Chemical business' which constitutes a single reportable segment in accordance with Ind AS 108 'Operating Segments'.

Board Meeting Details

The Meeting of the Board of Directors commenced at 01:30 P.M. (IST) and concluded at 04:05 P.M. (IST) on August 05, 2026.